Decreased AFP after treatment portends higher ORR and DCR.<h4>Conclusion</h4>TACE combined Lenvatinib plus Camrelizumab regimen was safe and superior to TACE alone in improving PFS, OS, and tumor response rates for unresectable recurrent HCC patients. This evidence concerns the gene AFP and hepatocellular carcinoma.